Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2002-05-13
2004-07-13
Solola, Taofiq (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C564S146000
Reexamination Certificate
active
06762316
ABSTRACT:
TECHNICAL FIELD
This invention relates to methods for preparing certain substituted cyclopentane compounds and certain intermediates thereof. The present invention is also concerned with novel intermediates or precursors for producing the substituted cyclopentane compounds. Substituted cyclopentane compounds prepared according to the present invention are useful as neuraminidase inhibitors, and especially in pharmaceutical composition for preventing, treating or ameliorating viral, bacterial and other infections.
BACKGROUND OF THE INVENTION
Despite the wealth of information available, influenza remains a potentially devastating disease of man, lower mammals, and birds. No effective vaccine exists and no cure is available once the infection has been initiated.
Influenza viruses consist of eight pieces of single stranded RNA, packaged in orderly fashion within the virion. Each piece codes for one of the major viral proteins. The replication complex is enclosed with a membrane composed of matrix protein associated with a lipid bilayer. Embedded in the lipid bilayer are two surface glycoprotein spikes, hemagglutinin (HA) and the enzyme neuraminidase (NA). All of the viral genes have been cloned and the three-dimensional structures of the surface glycoproteins have been determined.
Influenza viruses continually undergo antigenic variation in the two surface antigens, HA and NA, toward which neutralizing antibodies are directed. For this reason, vaccines and a subject's natural immune system have not been very effective. Attention is now being directed to finding other potential antiviral agents acting at other sites of the virion.
Furthermore, many other organisms carry NA. Many of these NA-possessing organisms are also major pathogens of man and/or mammals, including
Vibraeo cholerae, Clostridium perfringes, Streptococcus pneumonia, Arthrobacter sialophilas,
and other viruses, such as parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague virus, and Sendai virus. Compounds of this invention are also directed to inhibiting NA of these organisms.
In viruses, NA exists as a tetramer made of four roughly spherical subunits and a centrally-attached stalk containing a hydrophobic region by which it is embedded in the organism's membrane. Several roles have been suggested for NA. The enzyme catalyzes cleavage of the &agr;-ketosidic linkage between terminal sialic acid and an adjacent sugar residue. Removal of the sialic acid lowers the viscosity and permits access of the virus to the epithelial cells. NA also destroys the HA receptor on the host cell, thus allowing elution of progeny virus particles from infected cells.
Research indicates that the active site for influenza neuraminidase remains substantially unchanged for the major strains of influenza. For example, a comparison of sequences from influenza A subtypes and influenza B shows conserved residues with crucial structural and functional roles. Even though the sequence homology is only about 30%, many of the catalytic residues are conserved. Furthermore, the three-dimensional structures of influenza A and B neuraminidases have been determined. Superposition of the various structures shows remarkable structural similarity of the active site. Since the active site amino acid residues are conserved in all known influenza A neuraminidases that have been sequenced so far, an inhibitor that is effective against different strains of influenza A and/or B neuraminidase can be designed based on the three-dimensional structure of a neuraminidase.
In general, the role of NA is thought to be for the mobility of the virus both to and from the site of infections. Compounds that inhibit neuraminidase's activity may protect a subject from infection and/or cure a subject once infection has set in.
Analogs of neuraminic acid, such as 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and its derivatives are known to inhibit HA in vitro; however, these compounds are inactive in vivo. Palese and Schulman, in CHEMOPROPHYLAXIS AND VIRUS INFECTION OF THE UPPER RESPIRATORY TRACT, Vol. 1 (J. S. Oxford, Ed.), CRC Press, 1977, at PS 189-205.
Von Itzstein et al. describes cyclohexane analogs of &agr;-D-neuraminic acid of the formula
wherein:
A is O, C or S in Formula (a), and N or C in Formula (b); R
1
is CO
2
H, PO
3
H
2
, NO
2
, SO
2
H, SO
3
H, tetrazolyl-, CH
2
CHO, CHO, or CH(CHO)
2
;
R
2
is H, OR
6
, F, Cl, Br, CN, NHR
6
, SR
6
or CH
2
X, where X is NHR
6
halogen, or OR
6
;
R
3
and R
3
′ are H, CN, NHR
6
, SR
6
, ═NOR
6
, OR
6
, guanidino, NR
6
;
R
4
is NHR
6
, SR
6
, OR
6
, CO
2
R
6
, NO
2
, C(R
6
)
3.
, CH
2
CO
2
R
6
, CH
2
NO
2
or CH
2
NHR
6
;
R
5
is CH
2
YR
6
, CHYR
6
CH
2
YR
6
or CHYR
6
CHYR
6
CH
2
YR
6
;
R
6
is H, acyl, alkyl, allyl, or aryl;
Y is O, S, NH, or H;
and pharmaceutical salts thereof, useful as antiviral agents.
In addition, certain benzene derivatives are suggested in U.S. Pat. No. 5,453,533 as being inhibitors of influenza virus neuraminidase and various others are disclosed in U.S. patent application Ser. No. 08/413,886. Yamamoto et al. describe various sialic acid isomers as having inhibitory activity against neuraminidase in
Synthesis of Sialic Acid Isomers With Inhibitory Activity Against Neuraminidase,
TETRAHEDRON LETTERS, Vol. 33, No. 39, pp. 5791-5794, 1992.
WO 96/26933 to Gilead Sciences, Inc. describes certain 6-membered ring compounds as possible inhibitors of neuraminidase.
More recently, there have been disclosed new cyclopentane derivatives that are useful as neuraminidase inhibitors. For example, see WO 96/30329, assigned to BioCryst Pharmaceuticals, Inc., the assignee of the present application, the entire disclosure of which being incorporated herein by reference.
SUMMARY OF INVENTION
The present invention relates to methods for preparing certain substituted cyclopentane compounds that are useful as inhibitors of the enzyme neuraminidase. Moreover, the present invention is concerned with a method for preparing certain precursors of the substituted cyclopentane compounds.
The substituted cyclopentane compounds prepared according to the present invention are represented by the following formulae 1a and 1b:
wherein each R
1
individually is alkyl or substituted alkyl, alkenyl or substituted alkenyl of 1-6 carbon atoms, or H; each of R
2
and R
3
individually is alkyl or alkenyl of 1-8 carbon atoms, cycloalkyl or substituted cycloalkyl of 4-8 carbon atoms, aryl or substituted aryl, arylalkyl or substituted arylalkyl, or H provided at least one of R
2
and R
3
is other than H; X is NHR
1
, NHC (═NH) NHR
4
where R
4
is H, alkyl of 1-6 carbon atoms, OR
1
, COR
1
, COOR
1
, CN or NO
2
; A is H, F, OR
1
, OCOR
1
, —OOCNHR
1
, NHR
1
, or NHCOOR
1
; and
pharmaceutically acceptable salts thereof.
The precursors according to the present invention are isoxazoline derivatives represented by the following formula 4:
wherein R
2
and R
3
are the same as defined above and wherein each of Y and Z individually is COOR
1
or H provided that at least one of Y and Z is other than H.
The isoxazoline derivatives according to formula 4 are prepared according to the following procedure:
A nitrile oxide of the formula 2
is reacted with a cyclopentene derivative of the formula 3 to produce the desired isoxazoline derivative. R
2
, R
3
, Y and Z are the same as defined above.
The cyclopentane compounds of formula 1a can be prepared from the above isoxazoline derivatives by reducing the isoxazoline derivatives of formula 4 to form an aminoalcohol derivative according to formula 5. Reacting the aminoalcohol compound of formula 5 with an anhydride or acid halide of a carboxylic acid of the formula: R
1
COOH to produce the acylated compounds represented by formula 6. Next, the alcohol group of the acylated compounds is converted into a leaving group which in turn is displaced by ammonia or guanidine to produce compounds of formula 1a or the leaving group is displaced by an azide ion which in turn is converted to the guanidine using NH
2
compound.
In an alternative process for pr
Chand Pooran
Elliott Arthur J.
BioCryst Pharmaceuticals Inc.
Connolly Bove & Lodge & Hutz LLP
Solola Taofiq
LandOfFree
Preparation of substituted cyclopentane and cyclopentene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of substituted cyclopentane and cyclopentene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of substituted cyclopentane and cyclopentene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3202278